These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8786679)

  • 21. Bispecific antibodies: molecules that enable novel therapeutic strategies.
    Fischer N; Léger O
    Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
    Thakur A; Lum LG
    Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific antibodies for cancer immunotherapy: Current perspectives.
    Müller D; Kontermann RE
    BioDrugs; 2010 Apr; 24(2):89-98. PubMed ID: 20199124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy.
    Acheampong DO; Adokoh CK; Ampomah P; Agyirifor DS; Dadzie I; Ackah FA; Asiamah EA
    Protein Pept Lett; 2017; 24(5):456-465. PubMed ID: 28117014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antibody-conjugated cytostatic drugs. Uses of monoclonal antibodies for new strategies in tumor therapy].
    Renner C; Pfreundschuh M
    Fortschr Med; 1994 Oct; 112(29):399. PubMed ID: 8001887
    [No Abstract]   [Full Text] [Related]  

  • 26. Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies?
    Maher J; Adami AA
    Cancer Res; 2013 Sep; 73(18):5613-7. PubMed ID: 24014596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies for neoplastic disease solid tumors.
    Matthews IT
    Mol Biotechnol; 2002 May; 21(1):91-7. PubMed ID: 11989663
    [No Abstract]   [Full Text] [Related]  

  • 28. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.
    Yuraszeck T; Kasichayanula S; Benjamin JE
    Clin Pharmacol Ther; 2017 May; 101(5):634-645. PubMed ID: 28182247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A New Generation of "Magic Bullets" for Molecular Targeting of Cancer.
    Capala J; Kunos CA
    Clin Cancer Res; 2021 Jan; 27(2):377-379. PubMed ID: 33144340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibody therapy of cancer.
    Jurcic JG; Scheinberg DA; Houghton AN
    Cancer Chemother Biol Response Modif; 1997; 17():195-216. PubMed ID: 9551215
    [No Abstract]   [Full Text] [Related]  

  • 32. Biotechnology-2009 AAPS national conference. 21-24 June 2009, Seattle, WA, USA.
    Wu C
    IDrugs; 2009 Sep; 12(9):539-42. PubMed ID: 19697269
    [No Abstract]   [Full Text] [Related]  

  • 33. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.
    Correnti CE; Laszlo GS; de van der Schueren WJ; Godwin CD; Bandaranayake A; Busch MA; Gudgeon CJ; Bates OM; Olson JM; Mehlin C; Walter RB
    Leukemia; 2018 May; 32(5):1239-1243. PubMed ID: 29588544
    [No Abstract]   [Full Text] [Related]  

  • 34. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The new face of bispecific antibodies: targeting cancer and much more.
    Lum LG; Davol PA; Lee RJ
    Exp Hematol; 2006 Jan; 34(1):1-6. PubMed ID: 16413384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific antibodies: design, therapy, perspectives.
    Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
    Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology].
    Igawa T
    Yakugaku Zasshi; 2017; 137(7):831-836. PubMed ID: 28674296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Celgene wagers on Sutro's cell-free platform to ramp up ADCs.
    Ratner M
    Nat Biotechnol; 2014 Dec; 32(12):1175. PubMed ID: 25489819
    [No Abstract]   [Full Text] [Related]  

  • 39. A revolutionary therapeutic approach for psoriasis: bispecific biological agents.
    Torres T; Romanelli M; Chiricozzi A
    Expert Opin Investig Drugs; 2016 Jul; 25(7):751-4. PubMed ID: 27153320
    [No Abstract]   [Full Text] [Related]  

  • 40. Comments on the Fourth International Conference on Bispecific Antibodies and Cellular Cytotoxicity, Duck Key, Florida, March 1-5, 1995.
    Fanger MW; Ball ED; Drakeman DL
    J Hematother; 1995 Oct; 4(5):345-9. PubMed ID: 8581367
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.